1cvs › Citations

Structural basis for FGF receptor dimerization and activation.

Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M
Cell 98 641-50 (1999)
Cited: 327 times
EuropePMC logo PMID: 10490103

Abstract

The crystal structure of FGF2 bound to a naturally occurring variant of FGF receptor 1 (FGFR1) consisting of immunoglobulin-like domains 2 (D2) and 3 (D3) has been determined at 2.8 A resolution. Two FGF2:FGFR1 complexes form a 2-fold symmetric dimer. Within each complex, FGF2 interacts extensively with D2 and D3 as well as with the linker between the two domains. The dimer is stabilized by interactions between FGF2 and D2 of the adjoining complex and by a direct interaction between D2 of each receptor. A positively charged canyon formed by a cluster of exposed basic residues likely represents the heparin-binding site. A general model for FGF- and heparin-induced FGFR dimerization is inferred from the crystal structure, unifying a wealth of biochemical data.

Reviews - 1cvs mentioned but not cited (3)

  1. Integrating molecular networks with genetic variant interpretation for precision medicine. Capriotti E, Ozturk K, Carter H. Wiley Interdiscip Rev Syst Biol Med 11 e1443 (2019)
  2. Neuritogenic and neuroprotective properties of peptide agonists of the fibroblast growth factor receptor. Li S, Bock E, Berezin V. Int J Mol Sci 11 2291-2305 (2010)
  3. Pondering the mechanism of receptor tyrosine kinase activation: The case for ligand-specific dimer microstate ensembles. Karl K, Hristova K. Curr Opin Struct Biol 71 193-199 (2021)

Articles - 1cvs mentioned but not cited (22)

  1. Interrogating protein interaction networks through structural biology. Aloy P, Russell RB, Russell RB. Proc Natl Acad Sci U S A 99 5896-5901 (2002)
  2. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. Qing J, Du X, Chen Y, Chan P, Li H, Wu P, Marsters S, Stawicki S, Tien J, Totpal K, Ross S, Stinson S, Dornan D, French D, Wang QR, Stephan JP, Wu Y, Wiesmann C, Ashkenazi A. J Clin Invest 119 1216-1229 (2009)
  3. Heparan sulfate proteoglycans are ligands for receptor protein tyrosine phosphatase sigma. Aricescu AR, McKinnell IW, Halfter W, Stoker AW. Mol Cell Biol 22 1881-1892 (2002)
  4. Design of protein-binding proteins from the target structure alone. Cao L, Coventry B, Goreshnik I, Huang B, Sheffler W, Park JS, Jude KM, Marković I, Kadam RU, Verschueren KHG, Verstraete K, Walsh STR, Bennett N, Phal A, Yang A, Kozodoy L, DeWitt M, Picton L, Miller L, Strauch EM, DeBouver ND, Pires A, Bera AK, Halabiya S, Hammerson B, Yang W, Bernard S, Stewart L, Wilson IA, Ruohola-Baker H, Schlessinger J, Lee S, Savvides SN, Garcia KC, Baker D. Nature 605 551-560 (2022)
  5. Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. Goetz R, Ohnishi M, Ding X, Kurosu H, Wang L, Akiyoshi J, Ma J, Gai W, Sidis Y, Pitteloud N, Kuro-O M, Razzaque MS, Mohammadi M. Mol Cell Biol 32 1944-1954 (2012)
  6. Crystal structure of the agrin-responsive immunoglobulin-like domains 1 and 2 of the receptor tyrosine kinase MuSK. Stiegler AL, Burden SJ, Hubbard SR. J Mol Biol 364 424-433 (2006)
  7. Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization. Ibrahimi OA, Yeh BK, Eliseenkova AV, Zhang F, Olsen SK, Igarashi M, Aaronson SA, Linhardt RJ, Mohammadi M. Mol Cell Biol 25 671-684 (2005)
  8. Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate. Yeh BK, Eliseenkova AV, Plotnikov AN, Green D, Pinnell J, Polat T, Gritli-Linde A, Linhardt RJ, Mohammadi M. Mol Cell Biol 22 7184-7192 (2002)
  9. FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta HV, Rubinson DA, Fetter IJ, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais LK, Loftus M, Shinagare AB, Abrams TA, Clancy TE, Wang J, Patel AK, Brichory F, Vaslin Chessex A, Sullivan RJ, Keller RB, Denning S, Hill ER, Shapiro GI, Pokorska-Bocci A, Zanna C, Ng K, Schrag D, Jänne PA, Hahn WC, Cherniack AD, Corcoran RB, Meyerson M, Daina A, Zoete V, Bardeesy N, Wolpin BM. Cancer Discov 11 2488-2505 (2021)
  10. Plasticity in interactions of fibroblast growth factor 1 (FGF1) N terminus with FGF receptors underlies promiscuity of FGF1. Beenken A, Eliseenkova AV, Ibrahimi OA, Olsen SK, Mohammadi M. J Biol Chem 287 3067-3078 (2012)
  11. Fibroblast growth factor 2 dimer with superagonist in vitro activity improves granulation tissue formation during wound healing. Decker CG, Wang Y, Paluck SJ, Shen L, Loo JA, Levine AJ, Miller LS, Maynard HD. Biomaterials 81 157-168 (2016)
  12. A Heparin-Mimicking Block Copolymer Both Stabilizes and Increases the Activity of Fibroblast Growth Factor 2 (FGF2). Paluck SJ, Nguyen TH, Lee JP, Maynard HD. Biomacromolecules 17 3386-3395 (2016)
  13. A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth. Li D, Wei X, Xie K, Chen K, Li J, Fang J. Br J Cancer 111 68-77 (2014)
  14. GnRH Deficient Patients With Congenital Hypogonadotropic Hypogonadism: Novel Genetic Findings in ANOS1, RNF216, WDR11, FGFR1, CHD7, and POLR3A Genes in a Case Series and Review of the Literature. Neocleous V, Fanis P, Toumba M, Tanteles GA, Schiza M, Cinarli F, Nicolaides NC, Oulas A, Spyrou GM, Mantzoros CS, Vlachakis D, Skordis N, Phylactou LA. Front Endocrinol (Lausanne) 11 626 (2020)
  15. Predicting domain-domain interaction based on domain profiles with feature selection and support vector machines. González AJ, Liao L. BMC Bioinformatics 11 537 (2010)
  16. Identification of local conformational similarity in structurally variable regions of homologous proteins using protein blocks. Agarwal G, Mahajan S, Srinivasan N, de Brevern AG. PLoS One 6 e17826 (2011)
  17. Structure Activity Relationship of Heparin Mimicking Polymer p(SS-co-PEGMA): Effect of Sulfonation and Polymer Size on FGF2-Receptor Binding. Paluck SJ, Maynard HD. Polym Chem 8 4548-4556 (2017)
  18. FGF2-Derived PeptibodyF2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs into Cancer Cells Overexpressing FGFR1. Jendryczko K, Chudzian J, Skinder N, Opaliński Ł, Rzeszótko J, Wiedlocha A, Otlewski J, Szlachcic A. Cancers (Basel) 12 E2992 (2020)
  19. Isoform-specific inhibition of FGFR signaling achieved by a de-novo-designed mini-protein. Park JS, Choi J, Cao L, Mohanty J, Suzuki Y, Park A, Baker D, Schlessinger J, Lee S. Cell Rep 41 111545 (2022)
  20. The protein common assembly database (ProtCAD)-a comprehensive structural resource of protein complexes. Xu Q, Dunbrack RL. Nucleic Acids Res 51 D466-D478 (2023)
  21. Human Growth Factor/Immunoglobulin Complexes for Treatment of Myocardial Ischemia-Reperfusion Injury. Liebman B, Schwaegler C, Foote AT, Rao KS, Marquis T, Aronshtam A, Bell SP, Gogo P, LaChapelle RR, Spees JL. Front Bioeng Biotechnol 10 749787 (2022)
  22. Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action. Chan J, Chan J, Shao L, Stawicki SS, Pham VC, Akita RW, Hafner M, Crocker L, Yu K, Koerber JT, Schaefer G, Comps-Agrar L. J Biol Chem 299 102729 (2023)


Reviews citing this publication (85)

  1. Cell signaling by receptor tyrosine kinases. Schlessinger J. Cell 103 211-225 (2000)
  2. Cell signaling by receptor tyrosine kinases. Lemmon MA, Schlessinger J. Cell 141 1117-1134 (2010)
  3. Cellular signaling by fibroblast growth factor receptors. Eswarakumar VP, Lax I, Schlessinger J. Cytokine Growth Factor Rev 16 139-149 (2005)
  4. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Esko JD, Selleck SB. Annu Rev Biochem 71 435-471 (2002)
  5. Fibroblast growth factors. Ornitz DM, Itoh N. Genome Biol 2 REVIEWS3005 (2001)
  6. Role of tissue stroma in cancer cell invasion. De Wever O, Mareel M. J Pathol 200 429-447 (2003)
  7. Protein tyrosine kinase structure and function. Hubbard SR, Till JH. Annu Rev Biochem 69 373-398 (2000)
  8. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Cross MJ, Claesson-Welsh L. Trends Pharmacol Sci 22 201-207 (2001)
  9. Structural basis for fibroblast growth factor receptor activation. Mohammadi M, Olsen SK, Ibrahimi OA. Cytokine Growth Factor Rev 16 107-137 (2005)
  10. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Ornitz DM. Bioessays 22 108-112 (2000)
  11. Mechanisms underlying differential responses to FGF signaling. Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Cytokine Growth Factor Rev 16 233-247 (2005)
  12. Basement membranes: cell scaffoldings and signaling platforms. Yurchenco PD. Cold Spring Harb Perspect Biol 3 a004911 (2011)
  13. Exploring mechanisms of FGF signalling through the lens of structural biology. Goetz R, Mohammadi M. Nat Rev Mol Cell Biol 14 166-180 (2013)
  14. Structural systems biology: modelling protein interactions. Aloy P, Russell RB, Russell RB. Nat Rev Mol Cell Biol 7 188-197 (2006)
  15. Protein oligomerization: how and why. Ali MH, Imperiali B. Bioorg Med Chem 13 5013-5020 (2005)
  16. Glycomics approach to structure-function relationships of glycosaminoglycans. Sasisekharan R, Raman R, Prabhakar V. Annu Rev Biomed Eng 8 181-231 (2006)
  17. Role of heparan sulfate in fibroblast growth factor signalling: a structural view. Pellegrini L. Curr Opin Struct Biol 11 629-634 (2001)
  18. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. Dunn IF, Heese O, Black PM. J Neurooncol 50 121-137 (2000)
  19. Early anterior/posterior patterning of the midbrain and cerebellum. Liu A, Joyner AL. Annu Rev Neurosci 24 869-896 (2001)
  20. Interactions between Hedgehog proteins and their binding partners come into view. Beachy PA, Hymowitz SG, Lazarus RA, Leahy DJ, Siebold C. Genes Dev 24 2001-2012 (2010)
  21. Proteoglycans and pattern formation: sugar biochemistry meets developmental genetics. Selleck SB. Trends Genet 16 206-212 (2000)
  22. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Belov AA, Mohammadi M. Cold Spring Harb Perspect Biol 5 a015958 (2013)
  23. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. Mol Cancer 17 34 (2018)
  24. FGFs, their receptors, and human limb malformations: clinical and molecular correlations. Wilkie AO, Patey SJ, Kan SH, van den Ouweland AM, Hamel BC. Am J Med Genet 112 266-278 (2002)
  25. Structural biology of NCAM homophilic binding and activation of FGFR. Kiselyov VV, Soroka V, Berezin V, Bock E. J Neurochem 94 1169-1179 (2005)
  26. Structure and function of VEGF receptors. Stuttfeld E, Ballmer-Hofer K. IUBMB Life 61 915-922 (2009)
  27. CAMs and axonal growth: a critical evaluation of the role of calcium and the MAPK cascade. Doherty P, Williams G, Williams EJ. Mol Cell Neurosci 16 283-295 (2000)
  28. De-regulated FGF receptors as therapeutic targets in cancer. Knights V, Cook SJ. Pharmacol Ther 125 105-117 (2010)
  29. Genetic and hypoxic regulation of angiogenesis in gliomas. Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG. J Neurooncol 70 229-243 (2004)
  30. Order out of complexity--protein structures that interact with heparin. Mulloy B, Linhardt RJ. Curr Opin Struct Biol 11 623-628 (2001)
  31. Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases. Bae JH, Schlessinger J. Mol Cells 29 443-448 (2010)
  32. Biology of FGFRL1, the fifth fibroblast growth factor receptor. Trueb B. Cell Mol Life Sci 68 951-964 (2011)
  33. Perlecan and tumor angiogenesis. Jiang X, Couchman JR. J Histochem Cytochem 51 1393-1410 (2003)
  34. Signaling in cell differentiation and morphogenesis. Basson MA. Cold Spring Harb Perspect Biol 4 a008151 (2012)
  35. Regulating morphogen gradients in the Drosophila wing. Cadigan KM. Semin Cell Dev Biol 13 83-90 (2002)
  36. IgCAMs: bidirectional signals underlying neurite growth. Kamiguchi H, Lemmon V. Curr Opin Cell Biol 12 598-605 (2000)
  37. N-cadherin as a therapeutic target in cancer. Mariotti A, Perotti A, Sessa C, Rüegg C. Expert Opin Investig Drugs 16 451-465 (2007)
  38. Polyanions and the proteome. Jones LS, Yazzie B, Middaugh CR. Mol Cell Proteomics 3 746-769 (2004)
  39. Mechanistic diversity of cytokine receptor signaling across cell membranes. Stroud RM, Wells JA. Sci STKE 2004 re7 (2004)
  40. FGF Family: From Drug Development to Clinical Application. Hui Q, Jin Z, Li X, Liu C, Wang X. Int J Mol Sci 19 E1875 (2018)
  41. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Gasparini G. Crit Rev Oncol Hematol 37 97-114 (2001)
  42. Fibroblast growth factor signalling in osteoarthritis and cartilage repair. Xie Y, Zinkle A, Chen L, Mohammadi M. Nat Rev Rheumatol 16 547-564 (2020)
  43. The pleiotropic effects of fibroblast growth factor receptors in mammalian development. McIntosh I, Bellus GA, Jab EW. Cell Struct Funct 25 85-96 (2000)
  44. Kallmann syndrome: fibroblast growth factor signaling insufficiency? Dodé C, Hardelin JP. J Mol Med (Berl) 82 725-734 (2004)
  45. Cell sheet tissue engineering: Cell sheet preparation, harvesting/manipulation, and transplantation. Kobayashi J, Kikuchi A, Aoyagi T, Okano T. J Biomed Mater Res A 107 955-967 (2019)
  46. Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors. Dickson C, Spencer-Dene B, Dillon C, Fantl V. Breast Cancer Res 2 191-196 (2000)
  47. Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland. Delehedde M, Lyon M, Sergeant N, Rahmoune H, Fernig DG. J Mammary Gland Biol Neoplasia 6 253-273 (2001)
  48. FGFR signalling in women's cancers. Fearon AE, Gould CR, Grose RP. Int J Biochem Cell Biol 45 2832-2842 (2013)
  49. Isoforms of receptors of fibroblast growth factors. Gong SG. J Cell Physiol 229 1887-1895 (2014)
  50. Connecting signaling and cell cycle progression in growth factor-stimulated cells. Jones SM, Kazlauskas A. Oncogene 19 5558-5567 (2000)
  51. The structural biology of the FGF19 subfamily. Beenken A, Mohammadi M. Adv Exp Med Biol 728 1-24 (2012)
  52. Involvement of stromal proteoglycans in tumour progression. Wegrowski Y, Maquart FX. Crit Rev Oncol Hematol 49 259-268 (2004)
  53. Physical-chemical principles underlying RTK activation, and their implications for human disease. He L, Hristova K. Biochim Biophys Acta 1818 995-1005 (2012)
  54. Structural studies of GDNF family ligands with their receptors-Insights into ligand recognition and activation of receptor tyrosine kinase RET. Wang X. Biochim Biophys Acta 1834 2205-2212 (2013)
  55. Achondroplasia: pathogenesis and implications for future treatment. Laederich MB, Horton WA. Curr Opin Pediatr 22 516-523 (2010)
  56. Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting. Farrell B, Breeze AL. Biochem Soc Trans 46 1753-1770 (2018)
  57. Protein-protein interactions in receptor activation and intracellular signalling. Blundell TL, Burke DF, Chirgadze D, Dhanaraj V, Hyvönen M, Innis CA, Parisini E, Pellegrini L, Sayed M, Sibanda BL. Biol Chem 381 955-959 (2000)
  58. Receptor tyrosine kinase signaling: a view from quantitative proteomics. Dengjel J, Kratchmarova I, Blagoev B. Mol Biosyst 5 1112-1121 (2009)
  59. Transmembrane helix-helix interactions involved in ErbB receptor signaling. Cymer F, Schneider D. Cell Adh Migr 4 299-312 (2010)
  60. Fibroblast growth factor signaling in Caenorhabditis elegans. Borland CZ, Schutzman JL, Stern MJ. Bioessays 23 1120-1130 (2001)
  61. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies. Matsumura I, Mizuki M, Kanakura Y. Cancer Sci 99 479-485 (2008)
  62. Signaling by fibroblast growth factors: the inside story. Goldfarb M. Sci STKE 2001 pe37 (2001)
  63. Structural Biology of the FGF7 Subfamily. Zinkle A, Mohammadi M. Front Genet 10 102 (2019)
  64. Cell surface receptors. Deller MC, Yvonne Jones E. Curr Opin Struct Biol 10 213-219 (2000)
  65. Growth factors and steroid hormones: a complex interplay in the hypothalamic control of reproductive functions. Melcangi RC, Martini L, Galbiati M. Prog Neurobiol 67 421-449 (2002)
  66. The transition model of RTK activation: A quantitative framework for understanding RTK signaling and RTK modulator activity. Paul MD, Hristova K. Cytokine Growth Factor Rev 49 23-31 (2019)
  67. The Non-Fibrillar Side of Fibrosis: Contribution of the Basement Membrane, Proteoglycans, and Glycoproteins to Myocardial Fibrosis. Chute M, Aujla P, Jana S, Kassiri Z. J Cardiovasc Dev Dis 6 E35 (2019)
  68. FGFR3 targeting strategies for achondroplasia. Laederich MB, Horton WA. Expert Rev Mol Med 14 e11 (2012)
  69. Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer. Garje R, An J, Obeidat M, Kumar K, Yasin HA, Zakharia Y. Oncologist 25 e1711-e1719 (2020)
  70. Folding energetics and oligomerization of polytopic α-helical transmembrane proteins. Neumann J, Klein N, Otzen DE, Schneider D. Arch Biochem Biophys 564 281-296 (2014)
  71. Nonclassical transport proteins and peptides: an alternative to classical macromolecule delivery systems. Kueltzo LA, Middaugh CR. J Pharm Sci 92 1754-1772 (2003)
  72. Transplant immunobiology: a crucial role for heparan sulfate glycosaminoglycans? Ali S, Hardy LA, Kirby JA. Transplantation 75 1773-1782 (2003)
  73. Biological Significance and Targeting of the FGFR Axis in Cancer. Chioni AM, Grose RP. Cancers (Basel) 13 5681 (2021)
  74. Polarized Proteins in Endothelium and Their Contribution to Function. Wolpe AG, Ruddiman CA, Hall PJ, Isakson BE. J Vasc Res 58 65-91 (2021)
  75. Dual and antagonic therapeutic effects of sulfated glycans. Pomin VH. Bioorg Med Chem 24 3965-3971 (2016)
  76. Mendelian inheritance revisited: dominance and recessiveness in medical genetics. Zschocke J, Byers PH, Wilkie AOM. Nat Rev Genet 24 442-463 (2023)
  77. Peptides Derived from Growth Factors to Treat Alzheimer's Disease. Gascon S, Jann J, Langlois-Blais C, Plourde M, Lavoie C, Faucheux N. Int J Mol Sci 22 6071 (2021)
  78. Heparinoid Complex-Based Heparin-Binding Cytokines and Cell Delivery Carriers. Ishihara M, Nakamura S, Sato Y, Takayama T, Fukuda K, Fujita M, Murakami K, Yokoe H. Molecules 24 E4630 (2019)
  79. Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling. Nita A, Abraham SP, Krejci P, Bosakova M. Cells 10 1445 (2021)
  80. Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives. Loda A, Turati M, Semeraro F, Rezzola S, Ronca R. Int J Mol Sci 23 3835 (2022)
  81. Metabolic Messengers: fibroblast growth factor 1. Gasser E, Sancar G, Downes M, Evans RM. Nat Metab 4 663-671 (2022)
  82. On-off affinity binding modulation on thermoresponsive polymer-grafted surfaces for capture and release of proteins and cells. Kobayashi J, Yamato M, Okano T. J Biomater Sci Polym Ed 28 939-957 (2017)
  83. Putting two and two together: crystal structure of the FGF-receptor complex. Wiesmann C, de Vos AM. Structure 7 R251-5 (1999)
  84. A Role for Liquid-Ordered Plasma Membrane Nanodomains Coordinating the Unconventional Secretory Pathway of Fibroblast Growth Factor 2? Lolicato F, Nickel W. Front Cell Dev Biol 10 864257 (2022)
  85. The role of fibroblast growth factor 18 in cancers: functions and signaling pathways. Zhou Y, Sun S, Ling T, Chen Y, Zhou R, You Q. Front Oncol 13 1124520 (2023)

Articles citing this publication (217)

  1. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M. Mol Cell 6 743-750 (2000)
  2. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S. Cell 110 775-787 (2002)
  3. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Dodé C, Levilliers J, Dupont JM, De Paepe A, Le Dû N, Soussi-Yanicostas N, Coimbra RS, Delmaghani S, Compain-Nouaille S, Baverel F, Pêcheux C, Le Tessier D, Cruaud C, Delpech M, Speleman F, Vermeulen S, Amalfitano A, Bachelot Y, Bouchard P, Cabrol S, Carel JC, Delemarre-van de Waal H, Goulet-Salmon B, Kottler ML, Richard O, Sanchez-Franco F, Saura R, Young J, Petit C, Hardelin JP. Nat Genet 33 463-465 (2003)
  4. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL. Nature 407 1029-1034 (2000)
  5. CD44 is required for two consecutive steps in HGF/c-Met signaling. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. Genes Dev 16 3074-3086 (2002)
  6. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Suyama K, Shapiro I, Guttman M, Hazan RB. Cancer Cell 2 301-314 (2002)
  7. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Plotnikov AN, Hubbard SR, Schlessinger J, Mohammadi M. Cell 101 413-424 (2000)
  8. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Nature 410 604-608 (2001)
  9. α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Chen G, Liu Y, Goetz R, Fu L, Jayaraman S, Hu MC, Moe OW, Liang G, Li X, Mohammadi M. Nature 553 461-466 (2018)
  10. The relationship between sequence and interaction divergence in proteins. Aloy P, Ceulemans H, Stark A, Russell RB, Russell RB. J Mol Biol 332 989-998 (2003)
  11. Liver-specific activities of FGF19 require Klotho beta. Lin BC, Wang M, Blackmore C, Desnoyers LR. J Biol Chem 282 27277-27284 (2007)
  12. HSPG modification by the secreted enzyme Notum shapes the Wingless morphogen gradient. Giráldez AJ, Copley RR, Cohen SM. Dev Cell 2 667-676 (2002)
  13. Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis. Kan SH, Elanko N, Johnson D, Cornejo-Roldan L, Cook J, Reich EW, Tomkins S, Verloes A, Twigg SR, Rannan-Eliya S, McDonald-McGinn DM, Zackai EH, Wall SA, Muenke M, Wilkie AO. Am J Hum Genet 70 472-486 (2002)
  14. Identification of a new fibroblast growth factor receptor, FGFR5. Sleeman M, Fraser J, McDonald M, Yuan S, White D, Grandison P, Kumble K, Watson JD, Murison JG. Gene 271 171-182 (2001)
  15. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Yu K, Herr AB, Waksman G, Ornitz DM. Proc Natl Acad Sci U S A 97 14536-14541 (2000)
  16. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Olsen SK, Li JY, Bromleigh C, Eliseenkova AV, Ibrahimi OA, Lao Z, Zhang F, Linhardt RJ, Joyner AL, Mohammadi M. Genes Dev 20 185-198 (2006)
  17. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Olsen SK, Ibrahimi OA, Raucci A, Zhang F, Eliseenkova AV, Yayon A, Basilico C, Linhardt RJ, Schlessinger J, Mohammadi M. Proc Natl Acad Sci U S A 101 935-940 (2004)
  18. Structural interactions of fibroblast growth factor receptor with its ligands. Stauber DJ, DiGabriele AD, Hendrickson WA. Proc Natl Acad Sci U S A 97 49-54 (2000)
  19. N-Cadherin extracellular repeat 4 mediates epithelial to mesenchymal transition and increased motility. Kim JB, Islam S, Kim YJ, Prudoff RS, Sass KM, Wheelock MJ, Johnson KR. J Cell Biol 151 1193-1206 (2000)
  20. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. Cancer Cell 4 393-403 (2003)
  21. The Sema domain of Met is necessary for receptor dimerization and activation. Kong-Beltran M, Stamos J, Wickramasinghe D. Cancer Cell 6 75-84 (2004)
  22. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Ibrahimi OA, Eliseenkova AV, Plotnikov AN, Yu K, Ornitz DM, Mohammadi M. Proc Natl Acad Sci U S A 98 7182-7187 (2001)
  23. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Wu AL, Kolumam G, Stawicki S, Chen Y, Li J, Zavala-Solorio J, Phamluong K, Feng B, Li L, Marsters S, Kates L, van Bruggen N, Leabman M, Wong A, West D, Stern H, Luis E, Kim HS, Yansura D, Peterson AS, Filvaroff E, Wu Y, Sonoda J. Sci Transl Med 3 113ra126 (2011)
  24. Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Yeh BK, Igarashi M, Eliseenkova AV, Plotnikov AN, Sher I, Ron D, Aaronson SA, Mohammadi M. Proc Natl Acad Sci U S A 100 2266-2271 (2003)
  25. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H, Fujita T, Kuroki R, Yamashita T, Fukumoto S, Shimada T. J Bone Miner Res 23 1509-1518 (2008)
  26. Mechanism of FGF receptor dimerization and activation. Sarabipour S, Hristova K. Nat Commun 7 10262 (2016)
  27. Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides. Guimond SE, Turnbull JE. Curr Biol 9 1343-1346 (1999)
  28. Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Ibrahimi OA, Zhang F, Eliseenkova AV, Itoh N, Linhardt RJ, Mohammadi M. Hum Mol Genet 13 2313-2324 (2004)
  29. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. French DM, Lin BC, Wang M, Adams C, Shek T, Hötzel K, Bolon B, Ferrando R, Blackmore C, Schroeder K, Rodriguez LA, Hristopoulos M, Venook R, Ashkenazi A, Desnoyers LR. PLoS One 7 e36713 (2012)
  30. Fibroblast growth factor signaling and basement membrane assembly are connected during epithelial morphogenesis of the embryoid body. Li X, Chen Y, Schéele S, Arman E, Haffner-Krausz R, Ekblom P, Lonai P. J Cell Biol 153 811-822 (2001)
  31. Notch ligands are substrates for protein O-fucosyltransferase-1 and Fringe. Panin VM, Shao L, Lei L, Moloney DJ, Irvine KD, Haltiwanger RS. J Biol Chem 277 29945-29952 (2002)
  32. Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes. Ostrovsky O, Berman B, Gallagher J, Mulloy B, Fernig DG, Delehedde M, Ron D. J Biol Chem 277 2444-2453 (2002)
  33. Crystal structure of human stem cell factor: implication for stem cell factor receptor dimerization and activation. Zhang Z, Zhang R, Joachimiak A, Schlessinger J, Kong XP. Proc Natl Acad Sci U S A 97 7732-7737 (2000)
  34. Perlecan participates in proliferation activation of quiescent Drosophila neuroblasts. Voigt A, Pflanz R, Schäfer U, Jäckle H. Dev Dyn 224 403-412 (2002)
  35. The fibroblast growth factor receptor acid box is essential for interactions with N-cadherin and all of the major isoforms of neural cell adhesion molecule. Sanchez-Heras E, Howell FV, Williams G, Doherty P. J Biol Chem 281 35208-35216 (2006)
  36. A heparin-mimicking polymer conjugate stabilizes basic fibroblast growth factor. Nguyen TH, Kim SH, Decker CG, Wong DY, Loo JA, Maynard HD. Nat Chem 5 221-227 (2013)
  37. FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. Li E, You M, Hristova K. J Mol Biol 356 600-612 (2006)
  38. Structure of the active core of human stem cell factor and analysis of binding to its receptor kit. Jiang X, Gurel O, Mendiaz EA, Stearns GW, Clogston CL, Lu HS, Osslund TD, Syed RS, Langley KE, Hendrickson WA. EMBO J 19 3192-3203 (2000)
  39. FGF5 is a crucial regulator of hair length in humans. Higgins CA, Petukhova L, Harel S, Ho YY, Drill E, Shapiro L, Wajid M, Christiano AM. Proc Natl Acad Sci U S A 111 10648-10653 (2014)
  40. Fibroblast growth factor homologous factors are intracellular signaling proteins. Schoorlemmer J, Goldfarb M. Curr Biol 11 793-797 (2001)
  41. A novel mechanism of sequestering fibroblast growth factor 2 by glypican in lipid rafts, allowing skeletal muscle differentiation. Gutiérrez J, Brandan E. Mol Cell Biol 30 1634-1649 (2010)
  42. Attenuation of signaling pathways stimulated by pathologically activated FGF-receptor 2 mutants prevents craniosynostosis. Eswarakumar VP, Ozcan F, Lew ED, Bae JH, Tomé F, Booth CJ, Adams DJ, Lax I, Schlessinger J. Proc Natl Acad Sci U S A 103 18603-18608 (2006)
  43. Laminar patterning in the developing neocortex by temporally coordinated fibroblast growth factor signaling. Hasegawa H, Ashigaki S, Takamatsu M, Suzuki-Migishima R, Ohbayashi N, Itoh N, Takada S, Tanabe Y. J Neurosci 24 8711-8719 (2004)
  44. Preformed oligomeric epidermal growth factor receptors undergo an ectodomain structure change during signaling. Martin-Fernandez M, Clarke DT, Tobin MJ, Jones SV, Jones GR. Biophys J 82 2415-2427 (2002)
  45. Heparan sulfate acts as a bone morphogenetic protein coreceptor by facilitating ligand-induced receptor hetero-oligomerization. Kuo WJ, Digman MA, Lander AD. Mol Biol Cell 21 4028-4041 (2010)
  46. Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. Herbert C, Schieborr U, Saxena K, Juraszek J, De Smet F, Alcouffe C, Bianciotto M, Saladino G, Sibrac D, Kudlinzki D, Sreeramulu S, Brown A, Rigon P, Herault JP, Lassalle G, Blundell TL, Rousseau F, Gils A, Schymkowitz J, Tompa P, Herbert JM, Carmeliet P, Gervasio FL, Schwalbe H, Bono F. Cancer Cell 23 489-501 (2013)
  47. Homo-oligomer formation by basigin, an immunoglobulin superfamily member, via its N-terminal immunoglobulin domain. Yoshida S, Shibata M, Yamamoto S, Hagihara M, Asai N, Takahashi M, Mizutani S, Muramatsu T, Kadomatsu K. Eur J Biochem 267 4372-4380 (2000)
  48. FGF/heparin differentially regulates Schwann cell and olfactory ensheathing cell interactions with astrocytes: a role in astrocytosis. Santos-Silva A, Fairless R, Frame MC, Montague P, Smith GM, Toft A, Riddell JS, Barnett SC. J Neurosci 27 7154-7167 (2007)
  49. TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor. Arevalo JC, Conde B, Hempstead BL, Chao MV, Martin-Zanca D, Perez P. Mol Cell Biol 20 5908-5916 (2000)
  50. Towards a resolution of the stoichiometry of the fibroblast growth factor (FGF)-FGF receptor-heparin complex. Harmer NJ, Ilag LL, Mulloy B, Pellegrini L, Robinson CV, Blundell TL. J Mol Biol 339 821-834 (2004)
  51. Structural insights into proteoglycan-shaped Hedgehog signaling. Whalen DM, Malinauskas T, Gilbert RJ, Siebold C. Proc Natl Acad Sci U S A 110 16420-16425 (2013)
  52. Chemical Tumor Biology of Heparan Sulfate Proteoglycans. Raman K, Kuberan B. Curr Chem Biol 4 20-31 (2010)
  53. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Agazie YM, Movilla N, Ischenko I, Hayman MJ. Oncogene 22 6909-6918 (2003)
  54. Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. Receptor tyrosine kinase activation by laminin G-like domains. Sasaki T, Knyazev PG, Cheburkin Y, Göhring W, Tisi D, Ullrich A, Timpl R, Hohenester E. J Biol Chem 277 44164-44170 (2002)
  55. Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors. Fernández IS, Cuevas P, Angulo J, López-Navajas P, Canales-Mayordomo A, González-Corrochano R, Lozano RM, Valverde S, Jiménez-Barbero J, Romero A, Giménez-Gallego G. J Biol Chem 285 11714-11729 (2010)
  56. Activation of EGF receptor kinase by L1-mediated homophilic cell interactions. Islam R, Kristiansen LV, Romani S, Garcia-Alonso L, Hortsch M. Mol Biol Cell 15 2003-2012 (2004)
  57. Understanding the physical interactions in the FGF21/FGFR/β-Klotho complex: structural requirements and implications in FGF21 signaling. Yie J, Wang W, Deng L, Tam LT, Stevens J, Chen MM, Li Y, Xu J, Lindberg R, Hecht R, Véniant M, Chen C, Wang M. Chem Biol Drug Des 79 398-410 (2012)
  58. Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. De Cecco L, Marchionni L, Gariboldi M, Reid JF, Lagonigro MS, Caramuta S, Ferrario C, Bussani E, Mezzanzanica D, Turatti F, Delia D, Daidone MG, Oggionni M, Bertuletti N, Ditto A, Raspagliesi F, Pilotti S, Pierotti MA, Canevari S, Schneider C. Oncogene 23 8171-8183 (2004)
  59. Heparan sulphate proteoglycans modulate fibroblast growth factor-2 binding through a lipid raft-mediated mechanism. Chu CL, Buczek-Thomas JA, Nugent MA. Biochem J 379 331-341 (2004)
  60. Novel mechanisms of fibroblast growth factor receptor 1 regulation by extracellular matrix protein anosmin-1. Hu Y, Guimond SE, Travers P, Cadman S, Hohenester E, Turnbull JE, Kim SH, Bouloux PM. J Biol Chem 284 29905-29920 (2009)
  61. Nuclear trafficking of FGFR1: a role for the transmembrane domain. Myers JM, Martins GG, Ostrowski J, Stachowiak MK. J Cell Biochem 88 1273-1291 (2003)
  62. Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells. Pardo OE, Arcaro A, Salerno G, Tetley TD, Valovka T, Gout I, Seckl MJ. Oncogene 20 7658-7667 (2001)
  63. The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition. Kalinina J, Dutta K, Ilghari D, Beenken A, Goetz R, Eliseenkova AV, Cowburn D, Mohammadi M. Structure 20 77-88 (2012)
  64. A heparin-binding growth factor, midkine, binds to a chondroitin sulfate proteoglycan, PG-M/versican. Zou K, Muramatsu H, Ikematsu S, Sakuma S, Salama RH, Shinomura T, Kimata K, Muramatsu T. Eur J Biochem 267 4046-4053 (2000)
  65. The unconventional secretory machinery of fibroblast growth factor 2. Nickel W. Traffic 12 799-805 (2011)
  66. A novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasia. Winterpacht A, Hilbert K, Stelzer C, Schweikardt T, Decker H, Segerer H, Spranger J, Zabel B. Physiol Genomics 2 9-12 (2000)
  67. Fibronectin type III (FN3) modules of the neuronal cell adhesion molecule L1 interact directly with the fibroblast growth factor (FGF) receptor. Kulahin N, Li S, Hinsby A, Kiselyov V, Berezin V, Bock E. Mol Cell Neurosci 37 528-536 (2008)
  68. Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer β-amyloid peptide. Di Scala C, Troadec JD, Lelièvre C, Garmy N, Fantini J, Chahinian H. J Neurochem 128 186-195 (2014)
  69. Semirational design of a potent, artificial agonist of fibroblast growth factor receptors. Ballinger MD, Shyamala V, Forrest LD, Deuter-Reinhard M, Doyle LV, Wang JX, Panganiban-Lustan L, Stratton JR, Apell G, Winter JA, Doyle MV, Rosenberg S, Kavanaugh WM. Nat Biotechnol 17 1199-1204 (1999)
  70. Structure and response to flow of the glycocalyx layer. Cruz-Chu ER, Malafeev A, Pajarskas T, Pivkin IV, Koumoutsakos P. Biophys J 106 232-243 (2014)
  71. Differential expression of proteoglycans at central and peripheral nodes of Ranvier. Melendez-Vasquez C, Carey DJ, Zanazzi G, Reizes O, Maurel P, Salzer JL. Glia 52 301-308 (2005)
  72. Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis. Bellosta P, Iwahori A, Plotnikov AN, Eliseenkova AV, Basilico C, Mohammadi M. Mol Cell Biol 21 5946-5957 (2001)
  73. A structural and dynamic model for the interaction of interleukin-8 and glycosaminoglycans: support from isothermal fluorescence titrations. Krieger E, Geretti E, Brandner B, Goger B, Wells TN, Kungl AJ. Proteins 54 768-775 (2004)
  74. Discovery of a sulfated tetrapeptide that binds to vascular endothelial growth factor. Maynard HD, Hubbell JA. Acta Biomater 1 451-459 (2005)
  75. Evidence that Fgf10 contributes to the skeletal and visceral defects of an Apert syndrome mouse model. Hajihosseini MK, Duarte R, Pegrum J, Donjacour A, Lana-Elola E, Rice DP, Sharpe J, Dickson C. Dev Dyn 238 376-385 (2009)
  76. Energetics of ErbB1 transmembrane domain dimerization in lipid bilayers. Chen L, Merzlyakov M, Cohen T, Shai Y, Hristova K. Biophys J 96 4622-4630 (2009)
  77. A quantitative study of the recruitment potential of all intracellular tyrosine residues on EGFR, FGFR1 and IGF1R. Kaushansky A, Gordus A, Chang B, Rush J, MacBeath G. Mol Biosyst 4 643-653 (2008)
  78. Heparin sequencing brings structure to the function of complex oligosaccharides. Nugent MA. Proc Natl Acad Sci U S A 97 10301-10303 (2000)
  79. Transmembrane domain-mediated orientation of receptor monomers in active VEGFR-2 dimers. Dosch DD, Ballmer-Hofer K. FASEB J 24 32-38 (2010)
  80. Phosphorylation and lipid raft association of fibroblast growth factor receptor-2 in oligodendrocytes. Bryant MR, Marta CB, Kim FS, Bansal R. Glia 57 935-946 (2009)
  81. Ethanol inhibits L1 cell adhesion molecule activation of mitogen-activated protein kinases. Tang N, He M, O'Riordan MA, Farkas C, Buck K, Lemmon V, Bearer CF. J Neurochem 96 1480-1490 (2006)
  82. Multimers of the fibroblast growth factor (FGF)-FGF receptor-saccharide complex are formed on long oligomers of heparin. Harmer NJ, Robinson CJ, Adam LE, Ilag LL, Robinson CV, Gallagher JT, Blundell TL. Biochem J 393 741-748 (2006)
  83. Heparan sulfate separation, sequencing, and isomeric differentiation: ion mobility spectrometry reveals specific iduronic and glucuronic acid-containing hexasaccharides. Schenauer MR, Meissen JK, Seo Y, Ames JB, Leary JA. Anal Chem 81 10179-10185 (2009)
  84. Matrix-bound sixth Ig-like domain of cell adhesion molecule L1 acts as an angiogenic factor by ligating alphavbeta3-integrin and activating VEGF-R2. Hall H, Hubbell JA. Microvasc Res 68 169-178 (2004)
  85. Aromatic amino acids at the surface of InlB are essential for host cell invasion by Listeria monocytogenes. Machner MP, Frese S, Schubert WD, Orian-Rousseau V, Gherardi E, Wehland J, Niemann HH, Heinz DW. Mol Microbiol 48 1525-1536 (2003)
  86. A peptide from the first fibronectin domain of NCAM acts as an inverse agonist and stimulates FGF receptor activation, neurite outgrowth and survival. Anderson AA, Kendal CE, Garcia-Maya M, Kenny AV, Morris-Triggs SA, Wu T, Reynolds R, Hohenester E, Saffell JL. J Neurochem 95 570-583 (2005)
  87. Neuroligin-1 induces neurite outgrowth through interaction with neurexin-1β and activation of fibroblast growth factor receptor-1. Gjørlund MD, Nielsen J, Pankratova S, Li S, Korshunova I, Bock E, Berezin V. FASEB J 26 4174-4186 (2012)
  88. A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation. Arevalo JC, Conde B, Hempstead BI, Chao MV, Martín-Zanca D, Pérez P. Oncogene 20 1229-1234 (2001)
  89. Heparan sulfate proteoglycans and human breast cancer epithelial cell tumorigenicity. Okolicsanyi RK, van Wijnen AJ, Cool SM, Stein GS, Griffiths LR, Haupt LM. J Cell Biochem 115 967-976 (2014)
  90. Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. Kalinina J, Byron SA, Makarenkova HP, Olsen SK, Eliseenkova AV, Larochelle WJ, Dhanabal M, Blais S, Ornitz DM, Day LA, Neubert TA, Pollock PM, Mohammadi M. Mol Cell Biol 29 4663-4678 (2009)
  91. Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Corbo V, Beghelli S, Bersani S, Antonello D, Talamini G, Brunelli M, Capelli P, Falconi M, Scarpa A. Ann Oncol 23 127-134 (2012)
  92. The heparin-binding site of antithrombin is crucial for antiangiogenic activity. Zhang W, Swanson R, Izaguirre G, Xiong Y, Lau LF, Olson ST. Blood 106 1621-1628 (2005)
  93. Promotion of neurite outgrowth by fibroblast growth factor receptor 1 overexpression and lysosomal inhibition of receptor degradation in pheochromocytoma cells and adult sensory neurons. Hausott B, Schlick B, Vallant N, Dorn R, Klimaschewski L. Neuroscience 153 461-473 (2008)
  94. Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing. Tillman BN, Yanik M, Birkeland AC, Liu CJ, Hovelson DH, Cani AK, Palanisamy N, Carskadon S, Carey TE, Bradford CR, Tomlins SA, McHugh JB, Spector ME, Brenner JCh. Head Neck 38 Suppl 1 E1646-52 (2016)
  95. Screening a phage display library for a novel FGF8b-binding peptide with anti-tumor effect on prostate cancer. Wang W, Chen X, Li T, Li Y, Wang R, He D, Luo W, Li X, Wu X. Exp Cell Res 319 1156-1164 (2013)
  96. FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism. He L, Shobnam N, Wimley WC, Hristova K. J Biol Chem 286 13272-13281 (2011)
  97. FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. Hadari Y, Schlessinger J. J Clin Invest 119 1077-1079 (2009)
  98. Roles of heparan sulfate sulfation in dentinogenesis. Hayano S, Kurosaka H, Yanagita T, Kalus I, Milz F, Ishihara Y, Islam MN, Kawanabe N, Saito M, Kamioka H, Adachi T, Dierks T, Yamashiro T. J Biol Chem 287 12217-12229 (2012)
  99. Structural and functional characterization of alternative transmembrane domain conformations in VEGF receptor 2 activation. Manni S, Mineev KS, Usmanova D, Lyukmanova EN, Shulepko MA, Kirpichnikov MP, Winter J, Matkovic M, Deupi X, Arseniev AS, Ballmer-Hofer K. Structure 22 1077-1089 (2014)
  100. Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization. Guo H, Zhu Q, Yu X, Merugu SB, Mangukiya HB, Smith N, Li Z, Zhang B, Negi H, Rong R, Cheng K, Wu Z, Li D. Oncogene 36 5098-5109 (2017)
  101. A role for the perlecan protein core in the activation of the keratinocyte growth factor receptor. Ghiselli G, Eichstetter I, Iozzo RV. Biochem J 359 153-163 (2001)
  102. Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties. Facchiano A, Russo K, Facchiano AM, De Marchis F, Facchiano F, Ribatti D, Aguzzi MS, Capogrossi MC. J Biol Chem 278 8751-8760 (2003)
  103. Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases. Ren M, Qin H, Ren R, Tidwell J, Cowell JK. Cancer Res 71 7312-7322 (2011)
  104. Differential tyrosine phosphorylation of fibroblast growth factor (FGF) receptor-1 and receptor proximal signal transduction in response to FGF-2 and heparin. Lundin L, Rönnstrand L, Cross M, Hellberg C, Lindahl U, Claesson-Welsh L. Exp Cell Res 287 190-198 (2003)
  105. Elucidation of the mechanism of the regulatory function of the Ig1 module of the fibroblast growth factor receptor 1. Kiselyov VV, Kochoyan A, Poulsen FM, Bock E, Berezin V. Protein Sci 15 2318-2322 (2006)
  106. Heparan sulfation is essential for the prevention of cellular senescence. Jung SH, Lee HC, Yu DM, Kim BC, Park SM, Lee YS, Park HJ, Ko YG, Lee JS. Cell Death Differ 23 417-429 (2016)
  107. Neuritin Mediates Activity-Dependent Axonal Branch Formation in Part via FGF Signaling. Shimada T, Yoshida T, Yamagata K. J Neurosci 36 4534-4548 (2016)
  108. Heparin modulates the mitogenic activity of fibroblast growth factor by inducing dimerization of its receptor. a 3D view by using NMR. Nieto L, Canales Á, Fernández IS, Santillana E, González-Corrochano R, Redondo-Horcajo M, Cañada FJ, Nieto P, Martín-Lomas M, Giménez-Gallego G, Jiménez-Barbero J. Chembiochem 14 1732-1744 (2013)
  109. K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2 alpha and PLC gamma-independent pathways. Lievens PM, Roncador A, Liboi E. J Mol Biol 357 783-792 (2006)
  110. Fibroblast growth factor-derived peptides: functional agonists of the fibroblast growth factor receptor. Li S, Christensen C, Kiselyov VV, Køhler LB, Bock E, Berezin V. J Neurochem 104 667-682 (2008)
  111. Potential mechanisms for the regulation of growth factor binding by heparin. Forsten KE, Fannon M, Nugent MA. J Theor Biol 205 215-230 (2000)
  112. Spackling the crack: stabilizing human fibroblast growth factor-1 by targeting the N and C terminus beta-strand interactions. Dubey VK, Lee J, Somasundaram T, Blaber S, Blaber M. J Mol Biol 371 256-268 (2007)
  113. An atomic resolution structure for human fibroblast growth factor 1. Bernett MJ, Somasundaram T, Blaber M. Proteins 57 626-634 (2004)
  114. Poly(vinyl sulfonate) Facilitates bFGF-Induced Cell Proliferation. Nguyen TH, Paluck SJ, McGahran AJ, Maynard HD. Biomacromolecules 16 2684-2692 (2015)
  115. The physical basis of FGFR3 response to fgf1 and fgf2. Chen F, Hristova K. Biochemistry 50 8576-8582 (2011)
  116. FGFR4 and its novel splice form in myogenic cells: Interplay of glycosylation and tyrosine phosphorylation. Kwiatkowski BA, Kirillova I, Richard RE, Israeli D, Yablonka-Reuveni Z. J Cell Physiol 215 803-817 (2008)
  117. Molecular recognition of basic fibroblast growth factor by polyoxometalates. Wu Q, Wang J, Zhang L, Hong A, Ren J. Angew Chem Int Ed Engl 44 4048-4052 (2005)
  118. Oncogenic Ras-induced proliferation requires autocrine fibroblast growth factor 2 signaling in skeletal muscle cells. Fedorov YV, Rosenthal RS, Olwin BB. J Cell Biol 152 1301-1305 (2001)
  119. Vascular leakage in chick embryos after expression of a secreted binding protein for fibroblast growth factors. McDonnell K, Bowden ET, Cabal-Manzano R, Hoxter B, Riegel AT, Wellstein A. Lab Invest 85 747-755 (2005)
  120. Analysis of the fibroblast growth factor receptor (FGFR) signalling network with heparin as coreceptor: evidence for the expansion of the core FGFR signalling network. Xu R, Rudd TR, Hughes AJ, Siligardi G, Fernig DG, Yates EA. FEBS J 280 2260-2270 (2013)
  121. Interaction between 8-hydroxyquinoline ruthenium(II) complexes and basic fibroblast growth factors (bFGF): inhibiting angiogenesis and tumor growth through ERK and AKT signaling pathways. Yang L, Zhang J, Wang C, Qin X, Yu Q, Zhou Y, Liu J. Metallomics 6 518-531 (2014)
  122. Controlled release of vascular endothelial growth factor from alginate hydrogels nano-coated with polyelectrolyte multilayer films. Matsusaki M, Sakaguchi H, Serizawa T, Akashi M. J Biomater Sci Polym Ed 18 775-783 (2007)
  123. Ligand binding properties of binary complexes of heparin and immunoglobulin-like modules of FGF receptor 2. Uematsu F, Kan M, Wang F, Jang JH, Luo Y, McKeehan WL. Biochem Biophys Res Commun 272 830-836 (2000)
  124. Unliganded fibroblast growth factor receptor 1 forms density-independent dimers. Comps-Agrar L, Dunshee DR, Eaton DL, Sonoda J. J Biol Chem 290 24166-24177 (2015)
  125. FGFR3 transmembrane domain interactions persist in the presence of its extracellular domain. Sarabipour S, Hristova K. Biophys J 105 165-171 (2013)
  126. Isolation and characterization of human thyroid endothelial cells. Patel VA, Logan A, Watkinson JC, Uz-Zaman S, Sheppard MC, Ramsden JD, Eggo MC. Am J Physiol Endocrinol Metab 284 E168-76 (2003)
  127. Chick embryo lethal orphan virus can be polymer-coated and retargeted to infect mammalian cells. Stevenson M, Boos E, Herbert C, Hale A, Green N, Lyons M, Chandler L, Ulbrich K, van Rooijen N, Mautner V, Fisher K, Seymour L. Gene Ther 13 356-368 (2006)
  128. Comparative functional analysis of two fibroblast growth factor receptor 1 (FGFR1) mutations affecting the same residue (R254W and R254Q) in isolated hypogonadotropic hypogonadism (IHH). Koika V, Varnavas P, Valavani H, Sidis Y, Plummer L, Dwyer A, Quinton R, Kanaka-Gantenbein C, Pitteloud N, Sertedaki A, Dacou-Voutetakis C, Georgopoulos NA. Gene 516 146-151 (2013)
  129. Enzyme and integrin expression by high and low metastatic melanoma cell lines. Staquicini FI, Moreira CR, Nascimento FD, Tersariol IL, Nader HB, Dietrich CP, Lopes JD. Melanoma Res 13 11-18 (2003)
  130. High-throughput screening of gene function in stem cells using clonal microarrays. Ashton RS, Peltier J, Fasano CA, O'Neill A, Leonard J, Temple S, Schaffer DV, Kane RS. Stem Cells 25 2928-2935 (2007)
  131. LAMM syndrome with middle ear dysplasia associated with compound heterozygosity for FGF3 mutations. Sensi A, Ceruti S, Trevisi P, Gualandi F, Busi M, Donati I, Neri M, Ferlini A, Martini A. Am J Med Genet A 155A 1096-1101 (2011)
  132. NCAM-derived peptides function as agonists for the fibroblast growth factor receptor. Hansen SM, Køhler LB, Li S, Kiselyov V, Christensen C, Owczarek S, Bock E, Berezin V. J Neurochem 106 2030-2041 (2008)
  133. Predicting glycosaminoglycan surface protein interactions and implications for studying axonal growth. Griffith AR, Rogers CJ, Miller GM, Abrol R, Hsieh-Wilson LC, Goddard WA. Proc Natl Acad Sci U S A 114 13697-13702 (2017)
  134. Regulation of Receptor Binding Specificity of FGF9 by an Autoinhibitory Homodimerization. Liu Y, Ma J, Beenken A, Srinivasan L, Eliseenkova AV, Mohammadi M. Structure 25 1325-1336.e3 (2017)
  135. Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy. Ling L, Tan SK, Goh TH, Cheung E, Nurcombe V, van Wijnen AJ, Cool SM. Mol Cancer 14 136 (2015)
  136. An expandable, inducible hemangioblast state regulated by fibroblast growth factor. Vereide DT, Vickerman V, Swanson SA, Chu LF, McIntosh BE, Thomson JA. Stem Cell Reports 3 1043-1057 (2014)
  137. Effect of FGF-binding protein 3 on vascular permeability. Zhang W, Chen Y, Swift MR, Tassi E, Stylianou DC, Gibby KA, Riegel AT, Wellstein A. J Biol Chem 283 28329-28337 (2008)
  138. Fibro-porous meshes made from polyurethane micro-fibers: effects of surface charge on tissue response. Sanders JE, Lamont SE, Karchin A, Golledge SL, Ratner BD. Biomaterials 26 813-818 (2005)
  139. Fibroblast growth factor 2-stimulated proliferation is lower in muscle precursor cells from old rats. Jump SS, Childs TE, Zwetsloot KA, Booth FW, Lees SJ. Exp Physiol 94 739-748 (2009)
  140. Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7. Sher I, Lang T, Lubinsky-Mink S, Kuhn J, Adir N, Chatterjee S, Schomburg D, Ron D. J Biol Chem 275 34881-34886 (2000)
  141. Uptake of adenoviral vectors via fibroblast growth factor receptors involves intracellular pathways that differ from the targeting ligand. Hoganson DK, Sosnowski BA, Pierce GF, Doukas J. Mol Ther 3 105-112 (2001)
  142. Evolution of a protein folding nucleus. Xia X, Longo LM, Sutherland MA, Blaber M. Protein Sci 25 1227-1240 (2016)
  143. FGFs in endochondral skeletal development. Degnin CR, Laederich MB, Horton WA. J Cell Biochem 110 1046-1057 (2010)
  144. NMR structure of the first Ig module of mouse FGFR1. Kiselyov VV, Bock E, Berezin V, Poulsen FM. Protein Sci 15 1512-1515 (2006)
  145. Neuroprotective and memory enhancing properties of a dual agonist of the FGF receptor and NCAM. Enevoldsen MN, Kochoyan A, Jurgenson M, Jaako K, Dmytriyeva O, Walmod PS, Nielsen JD, Nielsen J, Li S, Korshunova I, Klementiev B, Novikova T, Zharkovsky A, Berezin V, Bock E. Neurobiol Dis 48 533-545 (2012)
  146. Structural basis for the activation of FGFR by NCAM. Kochoyan A, Poulsen FM, Berezin V, Bock E, Kiselyov VV. Protein Sci 17 1698-1705 (2008)
  147. Structural insights into the interaction of human S100B and basic fibroblast growth factor (FGF2): Effects on FGFR1 receptor signaling. Gupta AA, Chou RH, Li H, Yang LW, Yu C. Biochim Biophys Acta 1834 2606-2619 (2013)
  148. Synthesis of adenoviral targeting molecules by intein-mediated protein ligation. Nyanguile O, Dancik C, Blakemore J, Mulgrew K, Kaleko M, Stevenson SC. Gene Ther 10 1362-1369 (2003)
  149. The FGFR D3 domain determines receptor selectivity for fibroblast growth factor 21. Gupte J, Yang L, Wu X, Weiszmann J, Hecht R, Lemon B, Lindberg R, Wang Z, Li Y. J Mol Biol 408 491-502 (2011)
  150. The structural biology of growth factor receptor activation. Harmer NJ, Chirgadze D, Hyun Kim K, Pellegrini L, Blundell TL. Biophys Chem 100 545-553 (2003)
  151. Agonists of fibroblast growth factor receptor induce neurite outgrowth and survival of cerebellar granule neurons. Li S, Christensen C, Køhler LB, Kiselyov VV, Berezin V, Bock E. Dev Neurobiol 69 837-854 (2009)
  152. Apoptosis of granulosa cells and female infertility in achondroplastic mice expressing mutant fibroblast growth factor receptor 3G374R. Amsterdam A, Kannan K, Givol D, Yoshida Y, Tajima K, Dantes A. Mol Endocrinol 15 1610-1623 (2001)
  153. Bovine pituitary extract provides remarkable protection against oxidative stress in human prostate epithelial cells. Kent KD, Bomser JA. In Vitro Cell Dev Biol Anim 39 388-394 (2003)
  154. FGF-10 and its receptor exhibit bidirectional paracrine targeting to urothelial and smooth muscle cells in the lower urinary tract. Zhang D, Kosman J, Carmean N, Grady R, Bassuk JA. Am J Physiol Renal Physiol 291 F481-94 (2006)
  155. Gas-Phase Analysis of the Complex of Fibroblast GrowthFactor 1 with Heparan Sulfate: A Traveling Wave Ion Mobility Spectrometry (TWIMS) and Molecular Modeling Study. Zhao Y, Singh A, Xu Y, Zong C, Zhang F, Boons GJ, Liu J, Linhardt RJ, Woods RJ, Amster IJ. J Am Soc Mass Spectrom 28 96-109 (2017)
  156. Neuroprotective effects of a novel peptide, FK18, under oxygen-glucose deprivation in SH-SY5Y cells and retinal ischemia in rats via the Akt pathway. Xiong S, Xu Y, Ma M, Wang H, Wei F, Gu Q, Xu X. Neurochem Int 108 78-90 (2017)
  157. Coupling of transmembrane helix orientation to membrane release of the juxtamembrane region in FGFR3. Tamagaki H, Furukawa Y, Yamaguchi R, Hojo H, Aimoto S, Smith SO, Sato T. Biochemistry 53 5000-5007 (2014)
  158. Nature of Interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino])-bis-(1,3-naphtalene disulfonate). II. Removal of polar interactions affects protein folding. Zamai M, Hariharan C, Pines D, Safran M, Yayon A, Caiolfa VR, Cohen-Luria R, Pines E, Parola AH. Biophys J 82 2652-2664 (2002)
  159. S100A13-lipid interactions-role in the non-classical release of the acidic fibroblast growth factor. Kathir KM, Ibrahim K, Rajalingam D, Prudovsky I, Yu C, Kumar TK. Biochim Biophys Acta 1768 3080-3089 (2007)
  160. Stable Fibroblast Growth Factor 2 Dimers with High Pro-Survival and Mitogenic Potential. Nawrocka D, Krzyscik MA, Opaliński Ł, Zakrzewska M, Otlewski J. Int J Mol Sci 21 E4108 (2020)
  161. A Newly Defined and Xeno-Free Culture Medium Supports Every-Other-Day Medium Replacement in the Generation and Long-Term Cultivation of Human Pluripotent Stem Cells. Ahmadian Baghbaderani B, Tian X, Scotty Cadet J, Shah K, Walde A, Tran H, Kovarcik DP, Clarke D, Fellner T. PLoS One 11 e0161229 (2016)
  162. Fibroblast growth factor (FGF)-2 mediates cell attachment through interactions with two FGF receptor-1 isoforms and extracellular matrix or cell-associated heparan sulfate proteoglycans. Richard C, Roghani M, Moscatelli D. Biochem Biophys Res Commun 276 399-405 (2000)
  163. Parathyroid hormone is a heparin/polyanion binding protein: binding energetics and structure modification. Kamerzell TJ, Joshi SB, McClean D, Peplinskie L, Toney K, Papac D, Li M, Middaugh CR. Protein Sci 16 1193-1203 (2007)
  164. Peptides derived from specific interaction sites of the fibroblast growth factor 2-FGF receptor complexes induce receptor activation and signaling. Manfè V, Kochoyan A, Bock E, Berezin V. J Neurochem 114 74-86 (2010)
  165. Expression and glycosylation studies of human FGF receptor 4. Tuominen H, Heikinheimo P, Loo BM, Kataja K, Oker-Blom C, Uutela M, Jalkanen M, Goldman A. Protein Expr Purif 21 275-285 (2001)
  166. Genetic variations affecting serum carcinoembryonic antigen levels and status of regional lymph nodes in patients with sporadic colorectal cancer from Southern China. Liang Y, Tang W, Huang T, Gao Y, Tan A, Yang X, Zhang H, Hu Y, Qin X, Li S, Zhang S, Mo L, Liang Z, Shi D, Huang Z, Guan Y, Zhou J, Winkler C, O'Brien SJ, Xu J, Mo Z, Peng T. PLoS One 9 e97923 (2014)
  167. Multiple consequences of a single amino acid pathogenic RTK mutation: the A391E mutation in FGFR3. Chen F, Sarabipour S, Hristova K. PLoS One 8 e56521 (2013)
  168. Structure-based mutational analyses in FGF7 identify new residues involved in specific interaction with FGFR2IIIb. Sher I, Yeh BK, Mohammadi M, Adir N, Ron D. FEBS Lett 552 150-154 (2003)
  169. The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data. Wang Y, Gao W, Xu J, Chen X, Yang Y, Zhu Y, Yin Y, Guo R, Liu P, Shu Y, Liu L. Biomed Res Int 2015 763080 (2015)
  170. A role for chondroitin sulphate B in the activity of interleukin 12 in stimulating gamma-interferon secretion. Garnier P, Gibbs RV, Rider CC. Immunol Lett 85 53-58 (2003)
  171. ProNodal acts via FGFR3 to govern duration of Shh expression in the prechordal mesoderm. Ellis PS, Burbridge S, Soubes S, Ohyama K, Ben-Haim N, Chen C, Dale K, Shen MM, Shen MM, Constam D, Placzek M. Development 142 3821-3832 (2015)
  172. The interaction of heparin/polyanions with bovine, porcine, and human growth hormone. Joshi SB, Kamerzell TJ, McNown C, Middaugh CR. J Pharm Sci 97 1368-1385 (2008)
  173. Virion-associated viral fibroblast growth factor stimulates cell motility. Lehiy CJ, Martinez O, Passarelli AL. Virology 395 152-160 (2009)
  174. Zebrafish Ext2 is necessary for Fgf and Wnt signaling, but not for Hh signaling. Fischer S, Filipek-Gorniok B, Ledin J. BMC Dev Biol 11 53 (2011)
  175. Effect of the G375C and G346E achondroplasia mutations on FGFR3 activation. He L, Serrano C, Niphadkar N, Shobnam N, Hristova K. PLoS One 7 e34808 (2012)
  176. Membrane-Type 1 Matrix Metalloproteinase Downregulates Fibroblast Growth Factor-2 Binding to the Cell Surface and Intracellular Signaling. Tassone E, Valacca C, Mignatti P. J Cell Physiol 230 366-377 (2015)
  177. Quantitative assessment of FGF regulation by cell surface heparan sulfates. Berry D, Shriver Z, Venkataraman G, Sasisekharan R. Biochem Biophys Res Commun 314 994-1000 (2004)
  178. Sorting polyclonal antibodies into functionally distinct fractions using peptide phage display: 'a library on top of a library'. Moshitch-Moshkovitz S, Heldman Y, Yayon A, Katchalski-Katzir E. J Immunol Methods 242 183-191 (2000)
  179. WITHDRAWN: NCAM and the FGF-Receptor. Kiselyov VV. Neurochem Res (2008)
  180. research-article Activation of signaling receptors: do ligands bind to receptor monomer, dimer, or both? Pang X, Zhou HX. BMC Biophys 6 7 (2013)
  181. Disease-causing mutation in extracellular and intracellular domain of FGFR1 protein: computational approach. Rajith B, George Priya Doss C. Appl Biochem Biotechnol 169 1659-1671 (2013)
  182. Engineered variants of InlB with an additional leucine-rich repeat discriminate between physiologically relevant and packing contacts in crystal structures of the InlB:MET complex. Niemann HH, Gherardi E, Bleymüller WM, Heinz DW. Protein Sci 21 1528-1539 (2012)
  183. Evidence that the intracellular domain of FGF receptor 2IIIb affects contact of the ectodomain with two FGF7 ligands. Uematsu F, Jang JH, Kan M, Wang F, Luo Y, McKeehan WL. Biochem Biophys Res Commun 283 791-797 (2001)
  184. Expression and purification of recombinant human fibroblast growth factor receptor in Escherichia coli. Ryu EK, Cho KJ, Kim JK, Harmer NJ, Blundell TL, Kim KH. Protein Expr Purif 49 15-22 (2006)
  185. Ligand-induced coupling versus receptor pre-association: cellular automaton simulations of FGF-2 binding. Gopalakrishnan M, Forsten-Williams K, Täuber UC. J Theor Biol 227 239-251 (2004)
  186. Molecular cloning, overexpression, and characterization of the ligand-binding D2 domain of fibroblast growth factor receptor. Hung KW, Kumar TK, Chi YH, Chiu IM, Yu C. Biochem Biophys Res Commun 317 253-258 (2004)
  187. Letter A light scattering study of the interaction of fibroblast growth factor (FGF) with its receptor. Sharma P, Rajalingam D, Kumar TK, Singh S. Biophys J 94 L71-3 (2008)
  188. A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer. Fan L, Li W, Ying S, Shi L, Wang Z, Chen G, Ye H, Wu X, Wu J, Liang G, Li X. Tumour Biol 36 7233-7241 (2015)
  189. Binding of human recombinant mutant soluble ectodomain of FGFR2IIIc to c subtype of FGFRs: implications for anticancer activity. Liu Z, Liu G, Zhang GL, Li J, He YQ, Zhang SS, Wang Y, He WY, Cheng GH, Yang X, Xu J, Wang J. Oncotarget 7 68473-68488 (2016)
  190. Construction of a human monoclonal antibody against bFGF for suppression of NSCLC. Wang S, Qin Y, Wang Z, Xiang J, Zhang Y, Xu M, Li B, Xia Y, Zhang P, Wang H. J Cancer 9 2003-2011 (2018)
  191. Fibroblast growth factor (FGF)-21 signals through both FGF receptor-1 and 2. Ren G, Yin J, Wang W, Li L, Li D. Sci China Life Sci 53 1000-1008 (2010)
  192. Glycosyltransferases, sugar nucleotide transporters and bacterial surface lectins - at the cutting edge of glycobiology Rini JM, Sharon N. Curr Opin Struct Biol 10 507-509 (2000)
  193. Heparan sulphate proteoglycan in scleromyxedema promotes FGF-2 activity. Warner TF, Wrone DA, Williams EC, Cripps DJ, Mundhenke C, Friedl A. Pathol Res Pract 198 701-707 (2002)
  194. Hydrophobic scale: a second parameter to elucidating various specific ligand-protein interactions. Numao N, Fujii H, Fukazawa Y, Hanagata N, Tanaka K. Chem Pharm Bull (Tokyo) 52 377-379 (2004)
  195. Increase in gap junctional intercellular communication by high molecular weight hyaluronic acid associated with fibroblast growth factor 2 and keratinocyte growth factor production in normal human dermal fibroblasts. Park JU, Tsuchiya T. Tissue Eng 8 419-427 (2002)
  196. Maldevelopment of the submandibular gland in a mouse model of apert syndrome. Yamaji K, Morita J, Watanabe T, Gunjigake K, Nakatomi M, Shiga M, Ono K, Moriyama K, Kawamoto T. Dev Dyn 247 1175-1185 (2018)
  197. Molecular basis for the Kallmann syndrome-linked fibroblast growth factor receptor mutation. Thurman RD, Kathir KM, Rajalingam D, Kumar TK. Biochem Biophys Res Commun 425 673-678 (2012)
  198. Study of the interaction of the Ig2 module of the fibroblast growth factor receptor, FGFR Ig2, with the fibroblast growth factor 1, FGF1, by means of NMR spectroscopy. Kochoyan A, Poulsen FM, Berezin V, Bock E, Kiselyov VV. FEBS Lett 582 3374-3378 (2008)
  199. Development of a Monomeric Inhibitory RNA Aptamer Specific for FGFR3 that Acts as an Activator When Dimerized. Kamatkar N, Levy M, Hébert JM. Mol Ther Nucleic Acids 17 530-539 (2019)
  200. Dimerization effect of sucrose octasulfate on rat FGF1. Kulahin N, Kiselyov V, Kochoyan A, Kristensen O, Kastrup JS, Berezin V, Bock E, Gajhede M. Acta Crystallogr Sect F Struct Biol Cryst Commun 64 448-452 (2008)
  201. Heparin increases prolactin and modifies the effects of fgf-2 upon prolactin accumulation in pituitary primary cultures. Spuch C, Diz-Chaves Y, Pérez-Tilve D, Mallo F, Mallo F. Endocrine 24 131-136 (2004)
  202. Novel venom-based peptides (P13 and its derivative-M6) to maintain self-renewal of human embryonic stem cells by activating FGF and TGFβ signaling pathways. Ma R, Ren Z, Li B, Siu SWI, Chen G, Kwok HF. Stem Cell Res Ther 11 243 (2020)
  203. Schistosoma mansoni Fibroblast Growth Factor Receptor A Orchestrates Multiple Functions in Schistosome Biology and in the Host-Parasite Interplay. Du X, McManus DP, Fogarty CE, Jones MK, You H. Front Immunol 13 868077 (2022)
  204. Development of a high throughput screening assay for inhibitors of fibroblast growth factor-receptor-heparin interactions. Aviezer D, Seddon AP, Wildey MJ, Böhlen P, Yayon A. J Biomol Screen 6 171-177 (2001)
  205. Novel Bioluminescent Binding Assays for Ligand-Receptor Interaction Studies of the Fibroblast Growth Factor Family. Song G, Shao XX, Wu QP, Xu ZG, Liu YL, Guo ZY. PLoS One 11 e0159263 (2016)
  206. WITHDRAWN: Synthetic NCAM-derived Ligands of the Fibroblast Growth Factor Receptor. Hansen SM, Li S, Bock E, Berezin V. Neurochem Res (2008)
  207. An S116R Phosphorylation Site Mutation in Human Fibroblast Growth Factor-1 Differentially Affects Mitogenic and Glucose-Lowering Activities. Xia X, Kumru OS, Blaber SI, Middaugh CR, Li L, Ornitz DM, Suh JM, Atkins AR, Downes M, Evans RM, Tenorio CA, Bienkiewicz E, Blaber M. J Pharm Sci 105 3507-3519 (2016)
  208. Inhibition of FGFR Signaling by Targeting FGF/FGFR Extracellular Interactions: Towards the Comprehension of the Molecular Mechanism through NMR Approaches. Pagano K, Longhi E, Molinari H, Taraboletti G, Ragona L. Int J Mol Sci 23 10860 (2022)
  209. Letter Letter to the editor: 1H, 13C and 15N chemical shift assignments of the acidic fibroblast growth factor from Notopthalmus viridescens. Arunkumar AI, Srisailam S, Kumar TK, Kathir KM, Peng CL, Chen C, Chiu IM, Yu C. J Biomol NMR 17 279-280 (2000)
  210. Recombinant expression in E. coli of human FGFR2 with its transmembrane and extracellular domains. Bajinting A, Ng HL. PeerJ 5 e3512 (2017)
  211. Simultaneous binding of bFGF to both FGFR and integrin maintains properties of primed human induced pluripotent stem cells. Cheng YS, Taniguchi Y, Yunoki Y, Masai S, Nogi M, Doi H, Sekiguchi K, Nakagawa M. Regen Ther 25 113-127 (2024)
  212. So what do your sugars do? Hughes RC. Glycoconj J 17 567-575 (2000)
  213. A Detailed Protocol for Large-scale Recombinant Expression and Validation of Human FGFR2 with Its Transmembrane and Extracellular Domains in Escherichia coli. Bajinting A, Ng HL. Bio Protoc 9 e3261 (2019)
  214. A designed fusion tag for soluble expression and selective separation of extracellular domains of fibroblast growth factor receptors. Cheong DE, Choi HJ, Yoo SK, Lee HD, Kim GJ. Sci Rep 11 21453 (2021)
  215. An Evolutionary Strategy for Identification of Higher Order, Green Fluorescent Host-Guest Pairs Compatible with Living Systems. Casey GR, Zhou X, Lesiak L, Xu B, Fang Y, Becker DF, Stains CI. Chemistry 26 16721-16726 (2020)
  216. News Fashioning FGFs from phage? Wrighton N, Gearing D. Nat Biotechnol 17 1157-1158 (1999)
  217. Monoclonal antibodies with selective specificity towards different glycosylation isoforms of FGFR1. Gorbenko O, Ovcharenko G, Volkova D, Mayilo D, Gaman N, Khozhayenko Y, Usenko V, Gout I, Filonenko V. Hybridoma (Larchmt) 28 287-293 (2009)


Quick links